DCF Valuation
Foghorn Therapeutics Inc (FHTX) DCF Valuation — Is FHTX overvalued?
The estimated DCF fair value of one Foghorn Therapeutics Inc (FHTX) share is $0.14. Compared to the current market price of $4.88, the stock is overvalued by 97.2%.
DCF fair value
$0.14
Market price
$4.88
Upside / downside
−97.2%
Foghorn Therapeutics Inc (FHTX) DCF valuation FAQ
What is the DCF fair value of Foghorn Therapeutics Inc (FHTX)?
The discounted-cash-flow model estimates the intrinsic fair value of one Foghorn Therapeutics Inc (FHTX) share at $0.14, based on a 10-year projection of its cash flows converging to Damodaran industry averages.
Is Foghorn Therapeutics Inc (FHTX) overvalued or undervalued?
Against the current market price of $4.88, the DCF fair value of $0.14 implies FHTX is overvalued by 97.2%.
How is the FHTX DCF value calculated?
It is a 10-year discounted-cash-flow estimate built from Foghorn Therapeutics Inc's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when Foghorn Therapeutics Inc files a new quarterly or annual report.
How this FHTX valuation is built
The model projects ten years of Foghorn Therapeutics Inc's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing Foghorn Therapeutics Inc's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.
WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.
The market price refreshes daily; the DCF fair value updates when Foghorn Therapeutics Inc files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-06.